Weight Loss Drugs Spark Pharma Boom but Raise 'Bubble' Concerns, Deloitte Warns

Pharmaceutical research and development returns have surged to their highest in years, fueled by blockbuster weight loss and diabetes drugs like Wegovy and Zepbound. For the first time in 16 years, obesity treatments have overtaken oncology as the top contributor to late-stage pipeline value, according to a new Deloitte report.

While this boom has boosted profitability for leading pharma companies, experts warn it creates a risky concentration in the sector, potentially exposing it to shocks if demand or competition shifts. The report highlights a 'bubble effect' driven by a handful of GLP-1 drugs, masking a weaker underlying environment for the rest of the industry.

Obesity Drugs Outpace Oncology in Pharma Pipeline Value

Deloitte's latest analysis reveals that obesity and diabetes drugs now account for an estimated 38% of projected commercial inflows from the 2025 late-stage pharma pipeline. This marks a dramatic rise from just 1% in 2022, while oncology's share has dropped to 20%. The surge is almost entirely driven by glucagon-like peptide receptor agonists (GLP-1s), which have transformed treatment options.

A 'Bubble Effect' Raises Industry-Wide Risks

Hanno Ronte, Deloitte's Life Sciences and Healthcare Partner, describes the current pharma growth as a bubble due to the heavy concentration on a few blockbuster drugs. Just 54 mega-blockbuster indications, representing only 9% of the late-stage pipeline, are expected to generate about 70% of total risk-adjusted peak sales. This concentration heightens vulnerability to therapeutic-area-specific shocks.

"It is a bubble, because so much is concentrated. From a patient perspective, the bubble will not burst, and the drugs will not disappear, but we are reaching a point where vanity and health have collided, creating a transformative market with significant risks.",—Hanno Ronte, Deloitte

Uncertain Long-Term Impact of GLP-1 Drugs

While GLP-1 drugs have shown promise beyond weight loss and diabetes—such as reducing cardiovascular risks and treating sleep apnea—scientists are still exploring their full benefits and potential side effects. Recent trials investigating their impact on Alzheimer's disease progression yielded mixed results, and questions remain about effects on brain health and inflammation.

Additionally, GLP-1s have demonstrated potential in helping patients with addiction, fueling ongoing investment and interest in this drug class.

What Lies Ahead for Pharma Innovation?

The pharma industry faces a critical crossroads: continue to heavily invest in the current GLP-1 wave or pivot to discovering the next scientific breakthrough. The current concentration of returns in a few blockbuster drugs poses risks, but also opportunities for innovation and diversification.

"The question is, do you just double down on that – that's the bubble – or do you actually say 'we're going to try and find the next scientific wave'?"—Hanno Ronte, Deloitte